[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
December 22/29, 2004

Medicare Cancer Coverage

JAMA. 2004;292(24):2963. doi:10.1001/jama.292.24.2963-c

The US Centers for Medicare and Medicaid Services (CMS) has announced a plan to expand coverage for tests and treatments for cancer patients. The plan includes proposed coverage expansions for additional “off-label” uses in clinical studies for targeted cancer drugs that are already approved for colorectal cancer, including oxaliplatin, irinotecan hydrochloride, bevacizumab, and cetuximab. The plan also includes use of positron emission tomography scans for cervical cancer, and expansion of studies of such scans for diagnosing and staging other types of cancer. The CMS is seeking public comment on these proposals.

First Page Preview View Large
First page PDF preview
First page PDF preview
×